Since research on psychedelics was revived in the 2000s, prompted by the easing of the regulations that govern the substances, a lot of studies have shown that drugs such as LSD and psilocybin possess great therapeutic potential and can be used to treat conditions such as depression, anxiety and addiction.
These discoveries have led to the creation of companies that are focused on psychedelic therapy and that are working on finding ways in which these substances can be used in lieu of conventional medicine.
Among these companies is Small Pharma, a neuropharmaceutical firm based in the United Kingdom, which is carrying out the first clinical trial globally on DMT. The company’s main objective is to uncover whether the substance can help treat major depressive disorder.
This research could shift the focus away from selective serotonin reuptake inhibitors, which are currently used as antidepressants, towards psychedelics’ healing powers as well as revolutionize how professionals in the field of mental health approach therapy. The company’s chief scientific and medical officer Dr. Carol Routledge stated in an interview that she believes DMT-assisted psychotherapy may be among the best treatments in existence.
DMT is a chemical that occurs naturally and can be found in many animals and plants. Humans are known to produce DMT in the brain. The chemical, which is medically known as N, N-dimethyltryptamine, acts on the serotonin receptors in the brain, which leads to strong perceptual and emotional changes. The hallucinogenic induces intense psychedelic experiences in a matter of seconds after it has been ingested, with its effects only lasting a few minutes.
DMT’s psychological effects do not decrease with repeated dosing, with researchers finding that individuals who ingest the drug do not develop a tolerance for it.
Small Pharma started its first phase of the trial in February of this year, and the company will focus on exploring the effects of DMT-assisted therapy on healthy participants who have never ingested psychedelics. After the completion of the first phase, the company will begin the second phase of the trial, which will include enrolling participants who suffer from major depressive disorder.
Researchers note that while standard treatments such as SSRIs help stabilize patient moods, they don’t tackle the psychological issues that bring about depression or help every patient who uses them, which is where DMT comes in. DMT may, apart from fixing the underlying psychological issues that contribute to various mental health conditions, also have long-lasting psychological benefits for patients.
Scientists have found that the hallucinogen, just like other psychedelics, breaks the negative thought-pattern pathways that are common in mental health conditions and increases synaptic connectivity as well as neuronal connectivity.
The medical potential of DMT has encouraged many entities such as XPhyto Therapeutics Inc. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) to allocate significant amounts of resources to research the different medicinal applications to which this psychedelic compound can be put.
NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire is part of the InvestorBrandNetwork.